Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

mRNA giants make acquisitions

by Shi En Kim
January 12, 2023 | A version of this story appeared in Volume 101, Issue 2

 

Two of the pandemic’s most well-recognized messenger RNA (mRNA) vaccine developers have begun the new year with acquisitions. For $85 million, Moderna will purchase Japan-based OriCiro Genomics, which specializes in cell-free DNA synthesis and amplification technology. BioNTech will buy the London-headquartered company InstaDeep for $439 million and potentially up to $243 million in milestone payments. The transaction will allow BioNTech to leverage InstaDeep’s artificial intelligence and machine learning platforms for the discovery and development of immunotherapies and vaccines.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.